Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.

Alexey SurovAlexandra StrobelJan BorggrefeAndreas Wienke

Published in: European radiology (2023)

• Low skeletal muscle mass (LSMM) predicts treatment response (TR) to chemotherapy in the adjuvant and/or neoadjuvant setting. • LSMM predicts TR in immunotherapy. • LSMM does not influence TR in palliative chemotherapy.

Keyphrases

skeletal muscle
locally advanced
insulin resistance
palliative care
rectal cancer
early stage
squamous cell carcinoma
lymph node
radiation therapy
metabolic syndrome